Supplementary Figure S4 from Spatial Tumor Immune Microenvironment as a Prognostic and Predictive Biomarker in Anti–EGFR-Based Maintenance for RAS wt Metastatic CRC—The PanaMa (AIO KRK0212) Trial

Alexej Ballhausen; Susanna Swoboda; David Horst; Stefan Fruehauf; Ullrich Graeven; Lothar Müller; Tanja Trarbach; Ludwig Fischer von Weikersthal; Eray Goekkurt; Volker Heinemann; Stefan Kasper; Annika Kurreck; Annabel Helga Sophie Alig; Anke Reinacher‐Schick; Lars Bullinger; Arndt Stahler; Sebastian Stintzing; Armin Jarosch; Dominik Paul Modest

doi:10.1158/1078-0432.30255112

Key Points

High immune expression correlates with improved progression-free survival in metastatic CRC patients receiving maintenance therapy.
Mean values of epithelial tumor and stromal cells were analyzed to assess their impact on treatment outcomes in the trial.
Analysis covered various treatment arms, underscoring the significance of the tumor immune microenvironment as a predictive factor.
The findings imply biomarkers may enhance personalized treatment strategies for patients with RAS wt metastatic CRC.

Implication

Analysis shows high/low immune expression impacts progression-free survival in CRC, highlighting the role of biomarkers.

Abstract

Analysis of progression-free survival within the maintenance therapy set by high/low immune expression and treatment arm. Mean Values of Epithelial Tumor and Stromal Cells.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Ballhausen et al. (2025) studied this question.

synapsesocial.com/papers/68de68f183cbc991d0a21a3c https://doi.org/10.1158/1078-0432.30255112

View at Publisher

Ask AI

Bookmark

Share

Supplementary Figure S4 from Spatial Tumor Immune Microenvironment as a Prognostic and Predictive Biomarker in Anti–EGFR-Based Maintenance for RAS wt Metastatic CRC—The PanaMa (AIO KRK0212) Trial

Key Points

Implication

Abstract

Discussion

Cite This Study

Supplementary Figure S4 from Spatial Tumor Immune Microenvironment as a Prognostic and Predictive Biomarker in Anti–EGFR-Based Maintenance for RAS wt Metastatic CRC—The PanaMa (AIO KRK0212) Trial

Key Points

Implication

Abstract

Discussion

Cite This Study

Keep reading

More related papers

Keep reading

More related papers